CD4 and hepatocellular carcinoma: In addition, there are results showing that memory CD4+ T cells can recognize neoantigens and may lead to cancer remission after immunomodulation in the hepatocellular carcinoma (HCC) microenvironment after treatment with sorafenib (16).